Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROIBusiness Wire • 03/09/21
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROIBusiness Wire • 03/06/21
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic TherapyBusiness Wire • 03/06/21
Gilead Sciences, Inc. (GILD) Presents at Cowen 41st Annual Health Care Conference (Transcript)Seeking Alpha • 03/04/21
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health NeedsBusiness Wire • 03/02/21
Coronavirus News: Stock Market, Economy Continue Coronavirus ReboundInvestors Business Daily • 02/25/21
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphomaBusiness Wire • 02/10/21